Why Peptide Drugs Like GLP-1s Are Booming and What It Takes to Bring One to Market

Semaglutide generated over $25 billion in revenue in 2024. Tirzepatide is on track to match it. GLP-1 receptor agonists have become the most commercially significant drug class in a generation, and the ripple effects are reshaping how the entire pharmaceutical industry thinks about peptides as a therapeutic modality.

But the commercial success of these drugs can create a misleading impression of simplicity. Getting a peptide from a promising sequence on a screen to an approved medicine in a pharmacy is one of the most complex undertakings in drug development. The molecules are harder to make, harder to purify, and harder to file than conventional small molecules. Every step from synthesis through regulatory approval carries challenges that don’t exist for most other drug classes.

Understanding what that journey actually involves explains both why GLP-1s took decades to reach their current form and why the next wave of peptide therapeutics will depend on the same manufacturing depth.

Why GLP-1 Peptides Succeeded Where Earlier Attempts Failed

The GLP-1 receptor was identified as a therapeutic target in the 1980s. Native GLP-1, a 30-amino acid peptide produced in the gut, lowers blood sugar and reduces appetite. The problem was that it degrades in the bloodstream within minutes, making it useless as a drug without modification.

It took years of peptide development work to solve this. Exenatide, approved in 2005, used a naturally occurring peptide from Gila monster venom that mimics GLP-1 but resists degradation. Liraglutide attached a fatty acid chain to extend half-life through albumin binding. Semaglutide refined this approach further with a C18 fatty diacid and strategic amino acid substitutions that pushed dosing to once weekly.

Tirzepatide went further still, targeting both GLP-1 and GIP receptors in a single 39-amino acid molecule manufactured through a hybrid synthesis process that combined solid-phase and solution-phase chemistry.

Each of these molecules required years of peptide development to optimize the sequence, stabilize the molecule, and design a manufacturing process that could produce it consistently at commercial scale.

What It Actually Takes to Bring a Peptide Drug to Market

For companies working on peptide therapeutics, the path from candidate to approval involves several stages that each carry unique complexity. Companies evaluating how to access the right capabilities for this journey increasingly turn to partners offering dedicated peptide development services that span synthesis, analytics, and regulatory support under a single relationship.

Synthesis Route Selection

The first major decision is how to make the molecule. Short peptides under 15 amino acids may be produced efficiently by solution-phase synthesis. Medium-length sequences between 15 and 50 residues typically use solid-phase peptide synthesis. Longer or more complex molecules like tirzepatide require hybrid strategies that build fragments separately and assemble them in solution.

Getting this decision wrong early creates expensive problems later. A synthesis route optimized for speed at lab scale may generate unacceptable impurity profiles at commercial volumes, forcing a process change that delays the program by 12 to 18 months.

Purification at Scale

Purification is consistently the most expensive step in peptide development and manufacturing. Preparative reverse-phase HPLC is the industry standard, but its loading capacity limits throughput at commercial scale. For peptides with co-eluting deletion sequence impurities, standard methods may not achieve the purity levels regulators require without multiple passes or orthogonal techniques.

The purification strategy must be designed alongside the synthesis route, not after it. What comes out of the reactor determines what the chromatography column has to resolve.

Analytical Characterization

Peptide APIs face analytical demands that sit somewhere between small molecules and biologics. Identity testing, impurity profiling, counter-ion quantification, aggregation assessment, and stability studies all feed into the regulatory filing. Methods must be validated under ICH Q2(R2) and built to survive technology transfer to commercial quality control labs.

Peptide development programs that treat analytical work as an afterthought frequently discover gaps at filing stage that trigger Complete Response Letters and cost months of lost market access.

Regulatory Filing

The regulatory path for synthetic peptides has become clearer in recent years. The EMA’s dedicated synthetic peptide guideline, effective June 2026, covers manufacturing routes, impurity classification, and comparability requirements for the first time. FDA expectations around peptide impurity profiling have also tightened, particularly for ANDA submissions referencing innovator peptide products.

These frameworks provide more clarity, but they also raise the bar. Peptide development programs now need more comprehensive CMC documentation than was required even five years ago.

Why the Pipeline Is Only Getting More Complex

GLP-1 drugs proved the commercial viability of peptide therapeutics. The pipeline building behind them is even more ambitious.

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is in Phase 3 trials. Oral peptide formulations are moving beyond semaglutide, with cyclic peptide candidates targeting inflammatory conditions entering late-stage development. Peptide-drug conjugates are bringing cytotoxic payloads into oncology through peptide targeting sequences.

Each of these programs pushes peptide development further in terms of synthesis complexity, purification demands, and regulatory expectations. The manufacturing partners behind them will play an increasingly central role in determining which molecules make it from the lab to patients.

Where Neuland Laboratories Fits in This Picture

Neuland Laboratories operates as a peptide CDMO with capabilities spanning solid-phase, solution-phase, and hybrid synthesis routes. With dedicated peptide services and three cGMP-certified facilities, Neuland supports pharma and biotech clients through every stage of peptide development.

From early process scouting through commercial-scale GMP API manufacturing, Neuland provides end-to-end peptide development services. Their regulatory approvals from the FDA, EMA, and PMDA ensure the manufacturing data they generate meets the expectations of global regulatory review.

FAQs

1.  How long does it typically take to bring a peptide drug from discovery to FDA approval?

Most peptide programs take 8 to 12 years from initial candidate identification to regulatory approval. The timeline includes preclinical development, three phases of clinical trials, manufacturing scale-up, and regulatory review. Manufacturing complexity and analytical requirements often extend timelines beyond what comparable small molecule programs face.

2.  Why are GLP-1 drugs so much more expensive to manufacture than traditional oral medications?

GLP-1 manufacturing costs are driven by several factors that don’t apply to conventional tablets:

• Multi-step peptide synthesis requiring specialized equipment and costly reagents
• Preparative HPLC purification that can account for over half of total production cost
• Lipid or fatty acid conjugation steps that add manufacturing complexity
• Cold-chain storage and specialized formulation for injectable delivery

These requirements add up to per-gram API costs that are orders of magnitude higher than typical small molecules.

3. Can peptide drugs eventually become as affordable as generic small molecule medications?

Affordability will improve but likely won’t reach small molecule generic pricing levels. As patents expire, generic peptide manufacturers will enter the market, but the synthesis and purification infrastructure required will keep production costs higher than conventional generics. Process innovations like continuous manufacturing and improved purification technologies will help narrow the gap over time.

4. What makes a peptide drug candidate “developable” from a manufacturing perspective?

Developability depends on the sequence’s synthesizability, purification feasibility, and stability profile. Short to medium-length peptides without aggregation-prone regions and with well-understood impurity profiles are the most straightforward. Sequences containing multiple disulfide bonds, extensive post-translational modifications, or unusual non-natural amino acids require significantly more peptide development work before they’re ready for GMP production.